REGN — Regeneron Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $66.35bn
- $60.31bn
- $14.34bn
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
Drug developer Parabilis Medicines surges in Nasdaq debut
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Parabilis Medicines targets $2.3 billion valuation in upsized US IPO (updated)
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Brief: Parabilis Medicines - Estimated IPO Price Per Share Between $17 And $19 - SEC Filing
CytomX rises on expanded Regeneron deal worth up to $4 billion
CytomX rises on expanded Regeneron deal with up to $4 billion in milestones
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Brief: Regeneron’S Ebola Antibody Recommended By World Health Organization For Investigational Use In Response To Current Bundibugyo Ebolavirus Outbreak
WHO identifies Ebola treatments, vaccines be tested in trials amid outbreak (updated)
Brief: US Biotech Regeneron To Launch Global Capability Centre In India's Hyderabad - Statement
Factbox: Bundibugyo Ebola vaccines and treatments in development